Oncoinvent

Less than 1K followers

ONCIN

Oslo Børs

Biotechnology & Pharmaceuticals

Health Care

Oncoinvent is a clinical phase radiopharmaceutical company developing treatments for solid cancers. The technology platform is focused on the use of alpha-emitting radionuclides to deliver radiation directly to cancer cells. The Company's product candidate, Radspherin®, is an alpha radiation therapy candidate designed for the local treatment of cancer that has spread to body cavities. Oncoinvent has its headquarters in Oslo.

Market cap

-

Turnover

-

Revenue

23.04M

EBIT %

-687.2 %

P/E

-

Dividend yield-%

-

Financial calendar

20.5

2026

General meeting '26

27.8

2026

Interim report Q2'26

All

Press releases

ShowingAll content types

Regulatory press release10/29/2025, 4:38 PM

Oncoinvent AS: Merger of BerGenBio and Oncoinvent completed

Regulatory press release10/29/2025, 2:16 PM

Oncoinvent AS: Oncoinvent Presents Final Safety and Efficacy Results from the Phase 1/2a Trial of Radspherin® to Treat Colorectal Cancer at the 15th PSOGI International Congress on Peritoneal Surface Malignancies

Regulatory press release10/29/2025, 6:00 AM

Oncoinvent AS: BerGenBio and Oncoinvent - Last day of trading in the shares of Oncoinvent

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Regulatory press release10/24/2025, 5:59 AM

Oncoinvent AS: BerGenBio and Oncoinvent - Key Dates for Completion of Merger

Regulatory press release10/20/2025, 8:00 AM

ONCIN: Financial calendar

Regulatory press release10/8/2025, 5:00 AM

Oncoinvent AS: Oncoinvent Reports Positive Final Data from Phase 1 Trial of Radspherin® to Treat Ovarian Cancer

Regulatory press release8/29/2025, 5:00 AM

Oncoinvent AS: Thor Medical and Oncoinvent Enter Strategic Thorium-228 Supply Agreement

Regulatory press release8/27/2025, 5:00 AM

Oncoinvent ASA half-yearly report: Strong focus on financial discipline and advancing Phase 2 program in ovarian cancer

Regulatory press release8/22/2025, 10:22 AM

Oncoinvent ASA invites to a webcast presentation of 1H 2025 on Wednesday 27 August 2025

Regulatory press release8/4/2025, 11:53 AM

Oncoinvent AS: Oncoinvent shareholders approve the merger plan with BerGenBio

Regulatory press release7/3/2025, 1:45 PM

Oncoinvent ASA: Notice of Extraordinary General Meeting

Regulatory press release6/30/2025, 8:11 PM

Oncoinvent AS: Announcement of fully underwritten rights issue

Regulatory press release6/30/2025, 8:01 PM

Oncoinvent AS: BerGenBio and Oncoinvent, a rising innovator in radiopharmaceutical cancer therapies, announce proposed merger and a fully underwritten rights issue

Regulatory press release6/18/2025, 6:01 AM

Oncoinvent (ONCIN): Invitation to Presentation of Positive Final Data from Phase 1/2a Trial of Radspherin® in Patients with Colorectal Peritoneal Metastases

Regulatory press release6/18/2025, 5:00 AM

ONCIN: Oncoinvent Announces Positive Final Data from Phase 1/2a Trial of Radspherin® in Patients with Colorectal Peritoneal Metastases

Regulatory press release5/14/2025, 12:39 PM

ONCIN: Minutes from the annual general meeting 2025

Regulatory press release4/30/2025, 11:41 AM

ONCIN: Notice of Annual General Meeting

Regulatory press release4/28/2025, 6:22 PM

Oncoinvent ASA: Annual Report 2024

Regulatory press release4/28/2025, 6:05 AM

Oncoinvent ASA: Invitation to Presentation of Q1 2025 company update

Regulatory press release4/28/2025, 6:00 AM

Oncoinvent Reports updated 18-Month Data from Phase 1 Ovarian Cancer Trial with Radspherin®: No new recurrences Demonstrate Continued Promise of Preventing Disease Progression

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.